Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > ARCHIVE
ARCHIVE
- Pfizer Japan Files Public Knowledge-based Application for Diflucan
June 20, 2011
- US CRO to Provide Financial Support to Codevelopment Partner of MediBIC
June 20, 2011
- Amgen to Focus on 4 Fields Including Cancer Taking Advantage of Its Strength in Biotech
June 20, 2011
- Novartis Files Public Knowledge-based Applications for Add'l Indications for 3 More Products
June 20, 2011
- Takeda Presents PI Data on MLN4924 at ASCO
June 20, 2011
- Bayer to Strengthen Its PV Division
June 20, 2011
- FDA Approves pNET as Additional Indication for Sutent: Pfizer
June 20, 2011
- Axitinib Increases PFS Compared to Sorafenib in Previously Treated RCC Patients: ASCO
June 20, 2011
- Bayer to Accumulate Medicoeconomic Evidence
June 20, 2011
- MediBIC: Glufosfamide Granted Orphan Drug Status in Europe
June 20, 2011
- Korosho to Preferentially Support High-Quality Clinical Research
June 20, 2011
- ASKA Spreading Risks in Production, Distribution to Ensure Stable Supplies
June 20, 2011
- Korosho Calls For Development of 3 Drugs Used Off-label
June 20, 2011
- Reform Council Sees ¥1.6 Tril. Increase in Healthcare/Nursing Expenditure in FY2015
June 20, 2011
- Top-3 Dispensing Pharmacy Chains Report Record-high Sales, Profits Driven by New Store Openings
June 20, 2011
- Infections Added as Serious ADE for Revlimid: Safety Info.
June 20, 2011
- Korosho's Expert Committee Proposes Creation of “Pediatric Cancer Hub Hospitals”
June 20, 2011
- Major Drugstore Chains Report Increased Sales in Dispensing Business
June 20, 2011
- Top-4 Generic Makers Report Double-digit Growth in Sales, Profits
June 20, 2011
- Korosho to Permit Telemarketing of OTC Drugs to Residents of Isolated Islands for 2 More Years
June 20, 2011
ページ
Japan is ramping up its push to spread regional formularies nationwide, a policy expected to standardize treatments, strengthen supply resilience,…
We had just gotten off a call with a client in Europe, and we’d received a bit of an earful. “Philip,” the client pressed, “what can this candidate bring to us? We know what he does, but what has he…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…